| Literature DB >> 31912618 |
Ken Kurisu1,2,3, Yuya Tsurutani1, Kosuke Inoue4, Yoshitomo Hoshino1, Fumiko Saiki5, Kazuhiro Yoshiuchi3.
Abstract
The association of intra-individual variability in insulin requirements with C-reactive protein levels among acute phase patients remains unclear. This retrospective cohort study aimed to evaluate this association. Patients with type 2 diabetes undergoing surgery for lumbar spinal canal stenosis were included in the study. We analyzed 286 records of 49 patients using the linear mixed effects model. The model showed C-reactive protein levels to be significantly associated with insulin requirements, with an effect size of 0.60 U/day for an elevation of 1 mg/dL. The effect size was increased in patients with higher hemoglobin A1c levels. Our findings imply that C-reactive protein levels could be a useful clinical biomarker when blood glucose levels are controlled in acute phase patients.Entities:
Keywords: C-reactive protein; Insulin; Linear mixed effects model
Mesh:
Substances:
Year: 2020 PMID: 31912618 PMCID: PMC7378432 DOI: 10.1111/jdi.13210
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Characteristics of study participants
| Patients ( | ||
|---|---|---|
| Continuous variables | Mean (SD) | Median (IQR) |
| Age (years) | 74.04 (7.37) | 74 (11) |
| HbA1c (%) | 7.19 (1.01) | 6.9 (1.0) |
| eGFR (mL/min/1.73 m2) | 71.42 (15.91) | 72.70 (21.21) |
| BMI (kg/m2) | 24.58 (4.41) | 23.95 (3.97) |
| Glucose intake (g/day) | 190.67 (48.33) | 198.00 (65.90) |
| Peak CRP (mg/dL) | 7.14 (5.04) | 6.65 (7.74) |
| Peak ΔInsulin (U/day) | 7.61 (10.76) | 4 (8) |
No patient used glucagon‐like peptide‐1 receptor agonists. Δ, Differential value from the mean; BMI, body mass index; CRP, C‐reactive protein; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; IQR, interquartile range; OHA, oral hypoglycemic agent; SD, standard deviation.
Coefficients of the linear mixed‐effect model
| Total | Mean (95% CI) effect |
|
|---|---|---|
| Independent effects | ||
| Intercept | 3.11 (1.14 to 5.07) |
|
| ΔHbA1c (%) | 1.91 (−2.48 to 6.30) | 0.39 |
| CRP (mg/dL) | 0.60 (0.33 to 0.86) |
|
| OHA | −1.32 (−3.11 to 0.47) | 0.15 |
| Interactive effects | ||
| CRP × ΔHbA1c | 0.91 (0.52 to 1.30) |
|
| Glu (g/day) × ΔHbA1c | 0.0042 (−0.015 to 0.024) | 0.67 |
| OHA × ΔeGFR (mL/min/1.73 m2) | −0.089 (−0.18 to 0.0004) | 0.053 |
Bold values indicates P < 0.05.
Δ, Differential value from the mean; CI, confidence interval; CRP, C‐reactive protein; eGFR, estimated glomerular filtration rate; Glu, glucose intake; HbA1c, hemoglobin A1c; OHA, oral hypoglycemic agent use.
Figure 1Representation of the model and data. ΔInsulin represents the differential value of the doses of insulin administered compared to preoperative requirements. ΔHbA1c represents the remainder after subtracting the mean HbA1c of all patients (7.19%) from the HbA1c of each patient. The coefficients of the model are shown in Table 2. The data have been categorized into three groups based on hemoglobin A1c (HbA1c) levels, namely, high, moderate and low, with approximately one‐third of patients in each. The graphs have been drawn using the mean value in each group. (a) The mean ΔHbA1c of the high HbA1c group is 1.34; the graph has a steep slope. (b) The mean ΔHbA1c of the moderate HbA1c group is −0.18; the graph has a shallow slope. (c) The mean ΔHbA1c of the low HbA1c group is −0.86; the slope of the graph is almost flat.
Figure 2The relationship between the performance of the model and sample size. The model performance was evaluated based on the Pearson’s correlation coefficient between the predicted and actual amounts of ΔInsulin on fivefold cross‐validation, by increasing the study sample from small (n = 10) to the current entire cohort size (n = 49). The graph shows that after attaining a sample size of 30, the accuracy was almost saturated.